Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhGH for neurodevelopment in children with combined methylmalonic acidemia and homocystinuria
ChiCTR2100054613Phase 4Not yet recruiting
- Sponsor
- Zhengzhou Children's Hospital
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of peg-somatropin in Methylmalonic acidemia with homocystinemia (MMAHC) and methylmalonic acidemia (MMA) (2 arms), sponsored by Zhengzhou Children's Hospital. Primary endpoint: Total development quotient. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
peg-somatropin
03
Conditions
Methylmalonic acidemia with homocystinemia (MMAHC)methylmalonic acidemia (MMA)
Beyond the preview
Go deeper on ChiCTR2100054613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054613.